CDR2 divergent transcript (CDR2-DT)

CDR2 divergent transcript (CDR2-DT) is a long non-coding RNA gene located in proximity to the CDR2 gene. Divergent transcripts are defined as lncRNA genes transcribed in the opposite direction within a few hundred nucleotides of a protein-coding gene[7]. While CDR2-DT is catalogued in gene databases, its precise molecular function, biological role, and disease involvement remain uncharacterized in the literature and major reference sources[4][7]. There is currently no evidence supporting its use as a direct therapeutic target; nor are there clinical drugs, biomarkers, or safety issues described in the current research landscape. Key Points: - CDR2-DT is a long non-coding RNA (lncRNA) gene, not a protein, receptor, or druggable enzyme. - It does not have an established function or recognized disease role; no therapeutic or diagnostic drugs are reported to interact directly with CDR2-DT. - Searches frequently conflate "CDR2" (the protein-coding gene) with "CDR2-DT" (the non-coding RNA), but these are distinct molecular entities; this entry concerns only the latter[4][7]. - Divergent transcripts generally are thought to play roles in gene regulation and genome architecture, but evidence is speculative for CDR2-DT specifically[7][3][1]. Additional context: The most relevant gene entry (NCBI Gene ID 440346, Ensembl ENSG00000260790) provides only naming, molecular class, and genomic data, without supporting evidence of function, disease role, or targeting[4]. There is no indication that "CDR2 divergent transcript" is a canonical or actionable therapeutic target.

Other names

CDR2-DT